Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma
- Jiliang Qiu†1, 2,
- Pinzhu Huang†1,
- Qian Liu2,
- Jian Hong1,
- Binkui Li1,
- Canliang Lu1, 3,
- Li Wang1,
- Jianping Wang4 and
- Yunfei Yuan1Email author
© Qiu et al; licensee BioMed Central Ltd. 2011
Received: 14 May 2011
Accepted: 29 September 2011
Published: 29 September 2011
Metastasis-associated in colon cancer-1 (MACC1) is a newly identified gene that plays a role in colon cancer metastasis through upregulation of c-MET proto-oncogene (c-MET). However, the value of MACC1 as a potential biomarker for hepatocellular carcinoma (HCC) remains unknown.
MACC1 mRNA expression in 128 HCC tissues was examined by quantitative polymerase chain reaction. To show the potential correlation of MACC1 and c-MET, c-MET was also analysed.
MACC1 was more highly expressed in HCC than in non-HCC tissues (P = 0.009). High MACC1 expression was significantly increased in cases with high alpha fetoprotein (AFP) (P = 0.025). A positive correlation was found between MACC1 and c-MET mRNAs (r = 0.235, P = 0.009). Both univariate and multivariate analyses revealed that MACC1 expression was associated with overall survival (OS) and disease-free survival (DFS). Moreover, stratified analysis showed that tumour-node-metastasis (TNM) stage I patients with high MACC1 levels had shorter OS and DFS than those with low MACC1.
MACC1 may identify low- and high-risk individuals with HCC and be a valuable indicator for stratifying the prognosis of TNM stage I patients. MACC1 may serve as a novel biomarker for HCC.
KeywordsMACC1 c-MET hepatocellular carcinoma prognosis
Hepatocellular carcinoma (HCC) is one of the most common solid tumours and prevalent fatal cancers worldwide, especially in East Asia and Sub-Saharan Africa [1, 2]. Recently, HCC mortality rate has increased faster than the mortality rates for any other leading cancers in the United States [3, 4]. Surgical resection or liver transplantation offers the chance of a cure, but only 30-40% of HCC patients are eligible for curative treatments, even in developed countries . The HCC recurrence rate is as high as 54% at 5 years, even in early-stage HCC after radical resection [6, 7]. Survival may vary widely among HCC patients with the same clinicopathologic features, which is most likely attributable to the heterogeneity of the biological behaviour of tumour cells [8, 9]. Although recent studies have unravelled some aberrantly expressed genes contributing to different prognoses in HCC, the molecular markers that help to predict early recurrence and serve as potential targets remain limited.
The importance of understanding the molecular biology of HCC has recently gained considerable attention, as molecular targeting therapy has shown encouraging results for many malignancies [10, 11]. The key signal transduction pathways implicated in the pathogenesis of liver cancer include the PI3K/Akt/mTOR pathway , Wnt/β-catenin signalling cascade , and HGF/c-MET pathway . Recently, numerous disorders related to deregulation of the HGF/c-MET axis have been reported [15, 16]. Aberrant activity of c-MET elicits multiple cellular responses regulating cell morphogenesis, migration, and breakdown of the extracellular matrix. Dysregulation of c-MET is common in HCC , although the exact mechanisms of this pathway in the carcinogenesis of HCC are still under investigation. As compounds that target the HGF/c-MET pathway are developed, new treatments for c-MET-triggered malignancies may be designed and the sensitivity of molecular-targeted drugs that are in clinical use may be improved [18, 19].
Poor prognosis of HCC is often associated with a high potential of vascular invasion and metastasis [20, 21]. c-MET is one of the key players in the processes of dissociation, angiogenesis, and migration of tumour cells in HCC . Metastasis-associated in colon cancer-1 (MACC1), a new gene associated with colon cancer in primary and metastatic carcinomas, promotes tumour cell growth as well as the development of distant metastases . Overexpression of MACC1 induces downstream activation of HGF/c-MET and facilitates metastasis of colon cancer, while silencing of MACC1 leads to reduced tumour proliferation, decreased cell migration, and a lack of new metastases, indicating the importance of MACC1 in the phases of cancer progression. Although MACC1 has been studied in colon carcinoma, little is known about its role in HCC. To address this issue, we evaluated the expression of MACC1 mRNA to determine whether MACC1 expression is of prognostic significance in HCC. Given the tight correlation between MACC1 and c-MET in colon cancer, we also examined the expression level of c-MET mRNA to determine whether such correlation exists in HCC.
Four human HCC cell lines, specifically HepG2, SMMC-7721, MHCC-97H, and MHCC-97L, and one immortalised nontumourigenic normal human hepatocyte cell line, L-02, were used to screen the expression of MACC1. The hepatoma cell line HepG2 was purchased from the American Type Culture Collection (Manassas, VA). L-02, SMMC-7721, MHCC-97H and MHCC-97L were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and maintained under recommended culture conditions. Cells were grown at 37°C in a humidified incubator containing 5% CO2. RNA was extracted from exponentially growing cells.
Study population and sample collection
A total of 128 pairs of HCC tissues and adjacent nontumorous liver tissues were obtained from patients who underwent hepatectomy consecutively in a single group at the Department of Hepatobiliary Surgery, Sun Yat-sen Cancer Center, between January 2001 and December 2006 and who fulfilled the following criteria: (1) exclusive treatment with chemotherapy or radiotherapy before tumour excision, (2) no evidence of concomitant extrahepatic disease, (3) no simultaneous use of local treatment modalities (i.e., radiofrequency ablation, microwave ablation). The patients included 116 males (90.6%) and 12 females (9.4%), with a median age of 50 years (range 23-79 years). Tumour size ranged from 1.2 to 19.0 cm, with a median of 6.0 cm. All tumours were histologically diagnosed as HCC with Edmondson-Steiner grade I in 8 cases, grade II in 61, grade III in 54, and grade IV in 5. The tumour stages were classified according to the 6th Edition tumour-node-metastasis (TNM) classification of the International Union Against Cancer . Sixty-seven cases were classified as stage I, 26 as stage II, and 35 as stage III. In this study, non-tumorous tissues adjacent to tumour (NT) were defined as 2.0 cm from the margin, which were confirmed negative by histological examination, as used in other studies[24, 25]. Twenty normal non-cirrhotic liver tissue samples (N), which were from patients with liver haemangioma or focal nodular hyperplasia, were included as controls. All specimens were obtained immediately after surgical resection, snap-frozen in liquid nitrogen, and kept at -80°C until use. All recruited patients provided written informed consent before hepatectomy, and the study protocol was approved by the Ethics Committee of Sun Yat-sen University Cancer Center.
Reverse-transcription PCR analysis
All samples were evaluated in a blinded reverse-transcription polymerase chain reaction (RT-PCR) procedure without knowledge of the clinicopathological or follow-up data until the PCR results were finalised. PCR was performed as described previously . Briefly, total RNA was isolated with TRIzol-A+ agent and treated with DNase I (Invitrogen Inc., Carlsbad, CA) to remove DNA contamination. Reverse transcription was performed with the SuperScript RT kit (Promega Inc., Madison, WI) following the manufacturer's instructions. The cDNA templates were subjected to PCR amplification. The reaction conditions for MACC1 were as follows: pre-denaturation at 94° for 5 min; 34 cycles of denaturation at 94° for 30 s, annealing at 60° for 30 s and extension at 72° for 30 s; and final extension at 72° for 10 min. The final products were analysed by 2.0% agarose gel electrophoresis and stained with ethidium bromide. To detect any potential genomic DNA contamination, PCR reactions were also performed in RNA control samples that lacked reverse transcriptase during cDNA synthesis. Each PCR was performed in duplicate.
Real-time quantitative PCR analysis
Real-time quantitative PCR (Q-PCR) was performed in the same batch of cDNA prepared for RT-PCR to quantify MACC1 mRNA. Moreover, to explore the correlation of MACC1 and c-MET, c-MET mRNA was also quantified in 128 paired tumour specimens. The primer sets were 5'-TTCTTTTGATTCCTCCGGTGA-3' (forward) and 5'-ACTCTGATGGGCATGTGCTG-3' (reverse) for MACC1; 5'-GGATGCGTGCATTTATCAGA-3' (forward) and 5'-GTTGATAGGGCAGACGTTCG-3' (reverse) for 18s rRNA; and 5'-GCTAAAATGCTGGCACCCTAA-3' (forward) and 5'-ATAGTGCTCCCCAATGAAAGTAGAGA-3' (reverse) for c-Met. Q-PCR was performed with an ABI Prism 7900 HT Sequence Detection System (Applied Biosystems) and SYBR green I Master Mix kit (Invitrogen). 18s rRNA was analysed to normalise Q-PCR data. The threshold cycle (Ct) value for triplicate reactions was averaged, and the relative genomic expression was calculated by 2-ΔΔCt value [ΔCt = Ct (MACC1) - Ct (18s)] . Melting curves were performed to ensure only a single product was amplified.
The follow-up duration was defined as the interval between the date of operation and the date of death or last follow-up. The study was censored on 31 January 2010. The median follow-up time was 30.5 months, ranging from 3 to 85 months. All patients were followed up every 1-3 months in the first year and every 3-6 months thereafter. The follow-up protocol included physical examination, serum alpha-fetoprotein (AFP) level, chest X-ray, and abdominal ultrasonography. Computed tomography and/or magnetic resonance imaging and/or positron emission tomography were performed when intrahepatic relapse or distant metastasis was suspected. During the course of follow-up, 64 of 128 patients (50.0%) were found with intrahepatic recurrence, 18 patients (14.1%) developed distant metastases, 49 patients (38.3%) died of cancer-related causes, and 79 patients (61.7%) were still alive.
All statistical analyses were carried out using the SPSS 16.0 statistical software package (SPSS Inc., Chicago, IL). The chi-square test or Fisher's exact test was used to comparison of frequencies. Spearman's correlation test was applied to analyse the correlation. Overall and disease-free survival curves were generated using the Kaplan-Meier method, and the difference between curves was assessed by the log-rank test. Independent prognostic factors were estimated by the Cox proportional hazards stepwise regression model. All P values were 2-sided. A P value of less than 0.05 was considered statistically significant.
MACC1 expression in human hepatoma cell lines and HCC tissues
Similar results were obtained from the same batch of cell lines using Q-PCR, which indicated high MACC1 mRNA expression in liver cancer cell lines, while there was low expression in normal liver cells (Figure 1C). In 128 paired HCC patients' specimens, Q-PCR showed that MACC1 mRNA expression was higher in HCC tissues than in adjacent non-tumorous liver tissues or normal tissues (P = 0.009, P = 0.008, respectively) (Figure 1D). The dissociation curve showed a single peak as expected for MACC1 (data not shown). As we expected, Spearman's correlation test showed that the high-level expression of MACC1 detected by Q-PCR always indicated positive expression MACC1 according to RT-PCR (r = 0.223, P = 0.011).
Correlation between MACC1 and c-MET mRNA expression
Correlation of MACC1 mRNA expression and clinicopathologic parameters
Correlations between MACC1 mRNA expression and clinicopathologic features of HCC
MACC1 mRNA high level
Tumour size (cm)
Prognostic of HCC subtypes defined by MACC1 level
Univariate prognostic analysis of overall survival and disease-free survival in HCC patients
Overall survival rate (%)
Disease-free survival rate (%)
Female (n = 12)
Male (n = 116)
≤ 50 (n = 65)
> 50 (n = 63)
Negative (n = 18)
Positive (n = 110)
≤ 400 (n = 78)
> 400 (n = 50)
No (n = 13)
Yes (n = 115)
A (n = 116)
B (n = 12)
Tumour size (cm)
≤ 5 (n = 50)
> 5 (n = 78)
No (n = 91)
Yes (n = 37)
Complete (n = 32)
No/incomplete (n = 96)
No (n = 98)
Yes (n = 30)
I (n = 67)
II (n = 30)
III (n = 31)
I/II (n = 69)
III/IV (n = 59)
MACC1 expression level
Low (n = 71)
High (n = 57)
Multivariate analysis of factors contributing to overall survival and disease-free survival in HCC patients
HR (95% CI)
HR (95% CI)
MACC1 expression level
Stratified univariate and multivariate analysis
Univariate prognostic analysis of overall survival and disease-free survival in TNM stage I HCC patients
Overall survival rate (%)
Disease-free survival rate (%)
Female (n = 9)
Male (n = 58)
≤ 50 (n = 32)
> 50 (n = 35)
Negative (n = 13)
Positive (n = 54
≤ 400 (n = 43)
> 400 (n = 24)
No (n = 8)
Yes (n = 59)
A (n = 61)
B (n = 6)
Tumour size (cm)
≤ 5 (n = 40)
> 5 (n = 27)
Complete (n = 26)
No/incomplete (n = 41)
I/II (n = 46)
III/IV (n = 21)
MACC1 expression level
Low (n = 37)
High (n = 30)
Multivariate analysis of factors contributing to overall survival and disease-free survival in TNM stage I HCC patients
HR (95% CI)
HR (95% CI)
MACC1 expression level
The transcript levels of MACC1 in normal liver tissue are 14 × 106, as detected by expressed sequence tags (ESTs), compared with 20 × 106 in malignant liver tissue, according to the EST profile viewer of the NCBI UniGene database http://www.ncbi.nlm.gov/UniGene. These were supported by our study and another paper published recently. Shirahata et al.  showed that MACC1 expression was significantly correlated with vascular invasion and serum AFP level. However, with their small number of HCC patients (n = 30), statistical power was limited, and the authors did not explore its clinical predictive value for HCC patients. In this study, we analysed the mRNA expression of MACC1 in a relatively large population of HCC patients and correlated it with clinicopathological features and prognosis to determine whether this biomarker could predict disease outcomes. MACC1 expression in HCC tissue was significantly higher than in nonmalignant tissue. Importantly, high MACC1 expression was significantly correlated with more aggressive behaviour in terms of shorter OS and DFS and higher serum AFP, which is a putative clinicopathologic marker of HCC invasiveness and unfavourable prognosis . These data indicate that high MACC1 expression occurs in HCC and is associated with an aggressive invasion phenotype. Although elevated MACC1 expression was associated with high AFP in our study, which agrees with the data of Shirahata et al., no significant correlation has been observed between vascular invasion and MACC1 expression. This disparity presumably stems from different sample sizes and heterogeneity of study populations, which led to the relatively low proportion (4/30) of vascular invasion in the study of Shirahat's group . Stein et al. observed that high MACC1 levels indicated poor MFS for colon cancer. In contrast to colon cancer, intrahepatic metastasis is the most frequent pattern in the progression of HCC [5, 31], which may partially explain why no such relationship was found in this study. However, it is difficult to define whether intrahepatic recurrence after hepatectomy originates from either residual intrahepatic metastasis or metachronous multicentric carcinogenesis [32, 33]. Because the number of extrahepatic metastasis cases was limited in this study (n = 18), future studies are needed to address this issue more definitively.
Because MACC1 may promote cell migration and invasion by upregulating the downstream c-MET gene in colon cancer , we sought to determine whether such a mechanism might contribute to the increased invasiveness of HCC induced by MACC1. This study found a positive association between MACC1 and c-MET mRNA levels in HCC. This might support the existence of a regulatory and functional relationship between MACC1 and c-MET [34, 35]. Furthermore, based on c-MET contributes to the aggressiveness of HCC , this correlation might further indicate that MACC1 enhances the invasiveness of liver cancer cells.
Our study shows that MACC1 was expressed highly in HCC samples and cultured cancer cell lines. The mechanism of this high expression is still unclear, but it is interesting to note that chromosome region 7p21, which contains the MACC1 gene , frequently exhibits aberrant amplification of expression in HCC [37–39].
We hypothesised that high expression of MACC1 was causally associated with HCC invasion, based on several lines of evidence. First, we have shown that high MACC1 expression in human HCC was associated with higher serum AFP and shorter OS and DFS. Second, the level of MACC1 mRNA was high in MHCC-97H cells (Figure 1C), which are derived from the high-metastasis-potential cell line MHCC97 . Third, the level of MACC1 was positively correlated with that of c-MET, which plays critical roles in cancer cell migration and metastasis. Because this study enrolled mostly hepatitis B virus-dependent HCC patients (85.9%), it remains to be studied whether MACC1 as a marker of aggressive phenotype can be extended to HCC cases resulting from other aetiologies. Hepatitis virus-dependent and alcohol-dependent HCC display overexpression of MYC, whereas nonalcoholic steatohepatitis may evolve into malignancy via a MYC-independent mechanism, indicating that the existence of genetic discrepancies may occur via different aetiological routes . Whether MACC1 is associated with certain aetiological factors needs to be further investigated.
Clinical stage is the most important factor influencing the prognosis of HCC patients. Several systems are available to classify HCC. Among them, the International Union Against Cancer's TNM staging is one of the most prevalent. Although the TNM system has successfully graded patients on their prognosis according to clinicopathological variables, it has reached its limit in providing critical information that may influence treatment strategy. It is difficult for liver surgeons to predict exactly which individuals will experience relapse among early-stage patients who have undergone curative treatment. To overcome the limitations of these traditional systems, many molecular markers have been investigated and shown to have potential predictive significance. However, to date, biomarkers that could stratify HCC patients with curative excision in TNM stage I are still substantially limited. In our stratified analysis, we found that MACC1 mRNA expression had clear prognostic value for OS and DFS in TNM stage I patients. These data imply that MACC1 mRNA might act as a predictive tool to identify patients with TNM stage I at high risk of recurrence.
MACC1 may act as a key regulator of the HGF/c-MET pathway, leading to distant metastases in colon cancer . The relationships of MACC1 with other signalling molecules and pathways must be further evaluated to better understand the molecular pathogenesis of these tumours and develop more effective targeted therapeutic strategies.
This study established a correlation between MACC1 expression and HCC prognosis. MACC1 was highly expressed in HCC tissues and predicted the prognosis of HCC patients, suggesting MACC1 may be involved in the HCC malignant process. This information can be used to identify high-risk HCC patients who may benefit from more intensive treatment and follow-up care after resection of primary tumours. It also justifies further studies to gain insight into the underlying biology of MACC1 and to strive for a positive response after administration of innovative therapies targeted at MACC1.
List of abbreviations
reverse-transcription polymerase chain reaction
real-time quantitative PCR
metastasis-associated in colon cancer-1
hepatocyte growth factor
This work was supported by grants from the National Natural Science Foundation of China (30872489 and 30972916). The authors thank all the patients who participated in this study.
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.View ArticlePubMedGoogle Scholar
- El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007, 132: 2557-2576. 10.1053/j.gastro.2007.04.061.View ArticlePubMedGoogle Scholar
- Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009, 27: 1485-1491. 10.1200/JCO.2008.20.7753.PubMed CentralView ArticlePubMedGoogle Scholar
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.View ArticlePubMedGoogle Scholar
- Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet. 2003, 362: 1907-1917. 10.1016/S0140-6736(03)14964-1.View ArticlePubMedGoogle Scholar
- Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ, Wu F: Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg. 2009, 249: 118-123. 10.1097/SLA.0b013e3181904988.View ArticlePubMedGoogle Scholar
- Cherqui D, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, Duvoux C: Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg. 2009, 250: 738-746. 10.1097/SLA.0b013e3181bd582b.View ArticlePubMedGoogle Scholar
- Aravalli RN, Steer CJ, Cressman EN: Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008, 48: 2047-2063. 10.1002/hep.22580.View ArticlePubMedGoogle Scholar
- Dragani TA: Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010, 52: 252-257. 10.1016/j.jhep.2009.11.015.View ArticlePubMedGoogle Scholar
- Ma WW, Adjei AA: Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009, 59: 111-137. 10.3322/caac.20003.View ArticlePubMedGoogle Scholar
- Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008, 48: 1312-1327. 10.1002/hep.22506.PubMed CentralView ArticlePubMedGoogle Scholar
- Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008, 135: 1972-1983. 10.1053/j.gastro.2008.08.008. 1983 e1971-1911PubMed CentralView ArticlePubMedGoogle Scholar
- Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 2006, 127: 469-480. 10.1016/j.cell.2006.10.018.View ArticlePubMedGoogle Scholar
- Lai AZ, Abella JV, Park M: Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 2009, 19: 542-551. 10.1016/j.tcb.2009.07.002.View ArticlePubMedGoogle Scholar
- Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M: Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA. 2009, 106: 12903-12908. 10.1073/pnas.0810402106.PubMed CentralView ArticlePubMedGoogle Scholar
- Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M: Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009, 27: 1667-1674. 10.1200/JCO.2008.19.1635.PubMed CentralView ArticlePubMedGoogle Scholar
- Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS: Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006, 116: 1582-1595. 10.1172/JCI27236.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu X, Newton RC, Scherle PA: Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010, 16: 37-45. 10.1016/j.molmed.2009.11.005.View ArticlePubMedGoogle Scholar
- Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007, 316: 1039-1043. 10.1126/science.1141478.View ArticlePubMedGoogle Scholar
- Nathan H, Schulick RD, Choti MA, Pawlik TM: Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009, 249: 799-805. 10.1097/SLA.0b013e3181a38eb5.View ArticlePubMedGoogle Scholar
- Kim BK, Han KH, Park YN, Park MS, Kim KS, Choi JS, Moon BS, Chon CY, Moon YM, Ahn SH: Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol. 2008, 97: 246-252. 10.1002/jso.20953.View ArticlePubMedGoogle Scholar
- Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009, 15: 59-67. 10.1038/nm.1889.View ArticlePubMedGoogle Scholar
- Sobin LH, Wittekind C: International Union Against Cancer. TNM classification of malignant tumors. 2002, New York: John Wiley & Sons, 6Google Scholar
- Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ: Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007, 245: 36-43. 10.1097/01.sla.0000231758.07868.71.PubMed CentralView ArticlePubMedGoogle Scholar
- Tang SH, Yang DH, Huang W, Zhou HK, Lu XH, Ye G: Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population. Clin Cancer Res. 2006, 12: 4171-4177. 10.1158/1078-0432.CCR-05-2261.View ArticlePubMedGoogle Scholar
- Huang P, Qiu J, Li B, Hong J, Lu C, Wang L, Wang J, Hu Y, Jia W, Yuan Y: Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clin Biochem. 2011, 44: 582-589. 10.1016/j.clinbiochem.2011.02.012.View ArticlePubMedGoogle Scholar
- Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.View ArticlePubMedGoogle Scholar
- Mazumdar M, Smith A, Bacik J: Methods for categorizing a prognostic variable in a multivariable setting. Stat Med. 2003, 22: 559-571. 10.1002/sim.1333.View ArticlePubMedGoogle Scholar
- Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K: MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res. 2011, 31: 777-780.PubMedGoogle Scholar
- Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC: High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004, 112: 44-50. 10.1002/ijc.20279.View ArticlePubMedGoogle Scholar
- Katyal S, Oliver JH, Peterson MS, Ferris JV, Carr BS, Baron RL: Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000, 216: 698-703.View ArticlePubMedGoogle Scholar
- Sakon M, Umeshita K, Nagano H, Eguchi H, Kishimoto S, Miyamoto A, Ohshima S, Dono K, Nakamori S, Gotoh M, Monden M: Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg. 2000, 135: 1456-1459. 10.1001/archsurg.135.12.1456.View ArticlePubMedGoogle Scholar
- Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Shibata K, Ohta M, Kitano S: Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol. 2009, 35: 174-179. 10.1016/j.ejso.2008.01.027.View ArticlePubMedGoogle Scholar
- Stein U, Smith J, Walther W, Arlt F: MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle. 2009, 8: 2467-2469. 10.4161/cc.8.15.9018.View ArticlePubMedGoogle Scholar
- Arlt F, Stein U: Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol. 2009, 41: 2356-2359. 10.1016/j.biocel.2009.08.001.View ArticlePubMedGoogle Scholar
- Stein U, Dahlmann M, Walther W: MACC1 - more than metastasis? Facts and predictions about a novel gene. J Mol Med. 2010, 88: 11-18. 10.1007/s00109-009-0537-1.View ArticlePubMedGoogle Scholar
- Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, Wang XH, Du J, Liu YX, Sun BC: Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology. 2010, 51: 545-556.View ArticlePubMedGoogle Scholar
- Zimonjic DB, Keck CL, Thorgeirsson SS, Popescu NC: Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatology. 1999, 29: 1208-1214. 10.1002/hep.510290410.View ArticlePubMedGoogle Scholar
- Calvisi DF, Pinna F, Ladu S, Pellegrino R, Simile MM, Frau M, De Miglio MR, Tomasi ML, Sanna V, Muroni MR, Feo F, Pascale RM: Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut. 2009, 58: 679-687. 10.1136/gut.2008.152652.View ArticlePubMedGoogle Scholar
- Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, Xue Q: New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer. 1999, 81: 814-821. 10.1038/sj.bjc.6690769.PubMed CentralView ArticlePubMedGoogle Scholar
- Schlaeger C, Longerich T, Schiller C, Bewerunge P, Mehrabi A, Toedt G, Kleeff J, Ehemann V, Eils R, Lichter P, Schirmacher P, Radlwimmer B: Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology. 2008, 47: 511-520.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.